drugset
drugset / Trial / NCT00243854

Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

NCT00243854 ↗

Phase 1 Completed 8 enrolled Indiana University Genentech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva) in the treatment of patients with resectable pancreatic cancer.

Timeline

Start
2005-11
Primary completion
2010-08
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 100 mg —

Indications

malignant pancreatic neoplasm